Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells
暂无分享,去创建一个
Deenan Pillay | Clare Jolly | D. Pillay | C. Jolly | Boghuma Kabisen Titanji | Marlen Aasa-Chapman | M. Aasa-Chapman | B. Titanji
[1] John A. G. Briggs,et al. Virological Synapse-Mediated Spread of Human Immunodeficiency Virus Type 1 between T Cells Is Sensitive to Entry Inhibition , 2010, Journal of Virology.
[2] Q. Sattentau,et al. Cell-to-Cell Spread of Retroviruses , 2010, Viruses.
[3] K. Arastéh,et al. Clinical Pharmacokinetics of Darunavir , 2007, Clinical pharmacokinetics.
[4] S J Gange,et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy , 2009, Proceedings of the National Academy of Sciences.
[5] B. Clotet,et al. Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells , 2009, AIDS.
[6] Clare Jolly,et al. Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced restriction factors , 2011, Virology.
[7] Luis Apolonia,et al. Stable gene transfer to muscle using non-integrating lentiviral vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] Clare Jolly,et al. Cell-Cell Spread of Human Immunodeficiency Virus Type 1 Overcomes Tetherin/BST-2-Mediated Restriction in T cells , 2010, Journal of Virology.
[9] Dirk Jochmans,et al. TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates , 2005, Antimicrobial Agents and Chemotherapy.
[10] Q. Sattentau,et al. Avoiding the void: cell-to-cell spread of human viruses , 2008, Nature Reviews Microbiology.
[11] Claus O. Wilke,et al. Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells , 2006, Journal of Virology.
[12] D. Pillay,et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis , 2012, The Lancet.
[13] José A. Esté,et al. Antiretroviral Agents Effectively Block HIV Replication after Cell-to-Cell Transfer , 2012, Journal of Virology.
[14] C. B. Hare,et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy , 2010, AIDS.
[15] D. Back,et al. Review Darunavir: pharmacokinetics and drug interactions , 2008 .
[16] Q. Sattentau,et al. The Regulated Secretory Pathway in CD4+ T cells Contributes to Human Immunodeficiency Virus Type-1 Cell-to-Cell Spread at the Virological Synapse , 2011, PLoS pathogens.
[17] D. Fuchs,et al. Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy , 2010, Journal of acquired immune deficiency syndromes.
[18] James D. Campbell,et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.
[19] C. Boucher,et al. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review , 2009, AIDS.
[20] Katrien Fransen,et al. Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.
[21] Q. Sattentau,et al. Cell-to-cell HIV-1 spread and its implications for immune evasion , 2009, Current opinion in HIV and AIDS.
[22] Sarah Palmer,et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.
[23] David Back,et al. Darunavir: Pharmacokinetics and Drug Interactions , 2008, Antiviral therapy.
[24] D. Bennett,et al. Darunavir: pharmacokinetics and drug interactions. , 2008 .
[25] Q. Sattentau,et al. High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy , 2013, AIDS.
[26] Tara L. Kieffer,et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. , 2004, The Journal of infectious diseases.
[27] O. Schwartz,et al. Inefficient Human Immunodeficiency Virus Replication in Mobile Lymphocytes , 2006, Journal of Virology.
[28] W. Hübner,et al. Predominant Mode of Human Immunodeficiency Virus Transfer between T Cells Is Mediated by Sustained Env-Dependent Neutralization-Resistant Virological Synapses , 2007, Journal of Virology.
[29] Clare Jolly,et al. Requirement for an Intact T-Cell Actin and Tubulin Cytoskeleton for Efficient Assembly and Spread of Human Immunodeficiency Virus Type 1 , 2007, Journal of Virology.
[30] James E. Robinson,et al. Neutralization Resistance of Virological Synapse-Mediated HIV-1 Infection Is Regulated by the gp41 Cytoplasmic Tail , 2012, Journal of Virology.
[31] Clare Jolly,et al. HIV-1 Cell to Cell Transfer across an Env-induced, Actin-dependent Synapse , 2004, The Journal of experimental medicine.
[32] H. Kräusslich,et al. Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss , 2009, PLoS pathogens.
[33] R. Siliciano,et al. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. , 2013, BioEssays : news and reviews in molecular, cellular and developmental biology.
[34] R Blumenthal,et al. Quantitation of human immunodeficiency virus type 1 infection kinetics , 1993, Journal of virology.
[35] Richard D Moore,et al. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. , 2013, The Journal of clinical investigation.
[36] Joseph Sodroski,et al. Mode of Transmission Affects the Sensitivity of Human Immunodeficiency Virus Type 1 to Restriction by Rhesus TRIM5α , 2008, Journal of Virology.
[37] Walther Mothes,et al. In vivo imaging of virological synapses , 2012, Nature Communications.
[38] A. Trkola,et al. Cell-Cell Transmission Enables HIV-1 to Evade Inhibition by Potent CD4bs Directed Antibodies , 2012, PLoS pathogens.
[39] Ron Milo,et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy , 2011, Nature.
[40] J. Zamora,et al. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients , 2012, AIDS.
[41] Deenan Pillay,et al. Three Residues in HIV-1 Matrix Contribute to Protease Inhibitor Susceptibility and Replication Capacity , 2010, Antimicrobial Agents and Chemotherapy.
[42] A. D. Rodrigues,et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir , 1997, Antimicrobial agents and chemotherapy.
[43] C. Solas,et al. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: Clinical correlations , 2002, HIV clinical trials.
[44] Yang Wang,et al. Multiple Viral Genetic Analyses Detect Low-Level Human Immunodeficiency Virus Type 1 Replication during Effective Highly Active Antiretroviral Therapy , 2003, Journal of Virology.
[45] J. Baeten,et al. Antiretroviral-Based HIV-1 Prevention: Antiretroviral Treatment and Pre-Exposure Prophylaxis , 2012, Antiviral therapy.
[46] M. Huber,et al. Directed Egress of Animal Viruses Promotes Cell-to-Cell Spread , 2002, Journal of Virology.
[47] Frank Y. S. Chuang,et al. Quantitative 3D Video Microscopy of HIV Transfer Across T Cell Virological Synapses , 2009, Science.
[48] Andrew D. Luster,et al. HIV-infected T cells are migratory vehicles for viral dissemination , 2012, Nature.
[49] Q. Sattentau,et al. Retroviral Spread by Induction of Virological Synapses , 2004, Traffic.
[50] G. Heidecker,et al. Quantitative Comparison of HTLV-1 and HIV-1 Cell-to-Cell Infection with New Replication Dependent Vectors , 2010, PLoS pathogens.
[51] J. Arribas,et al. Protease inhibitor monotherapy , 2011, Current opinion in infectious diseases.
[52] H. Sticht,et al. Effects of the V82A and I54V mutations on the dynamics and ligand binding properties of HIV-1 protease , 2010, Journal of molecular modeling.
[53] O. Schwartz,et al. Tetherin Restricts Productive HIV-1 Cell-to-Cell Transmission , 2010, PLoS pathogens.